
BusinessReported
Haleon Reports Sales Boost by Targeting Consumers on Weight-Loss Drugs
The maker of Advil is capitalizing on the popularity of GLP-1 weight-loss medications, according to a report by CNBC.
· 1 min read

The maker of Advil is capitalizing on the popularity of GLP-1 weight-loss medications, according to a report by CNBC.
Research cited by Scientific American found that giving older mice the GLP-1 drug semaglutide, sold as Wegovy or Ozempic, notably extended their lifespan, though implications for humans remain unclear.

Fake versions of retatrutide are proliferating online despite the medication not yet being approved by regulators.